J
Julio Rosenstock
Researcher at University of Texas Southwestern Medical Center
Publications - 423
Citations - 39792
Julio Rosenstock is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 94, co-authored 364 publications receiving 32784 citations. Previous affiliations of Julio Rosenstock include Medical City Dallas Hospital & Pfizer.
Papers
More filters
Journal ArticleDOI
747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5
W. Timothy Garvey,Rachel L. Batterham,Julio Rosenstock,Minzhi Liu,Vivian T. Thieu,Brandon K. Bergman +5 more
TL;DR: In this paper , the authors assess the time spent with weight loss ≥ 5% in participants with T2D randomized to the GIP/GLP-1 receptor agonist tirzepatide (TZP) vs comparators in SURPASS 1-5.
Journal ArticleDOI
775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis
Medha Munshi,Robert A. Ritzel,Rory J. McCrimmon,Irene Hramiak,Felipe Lauand,Lydie Melas-Melt,Elisabeth Souhami,Julio Rosenstock +7 more
TL;DR: In this article , the authors identify factors associated with achieving target HbA1c <7% and derived Time in Range (dTIR) ≥70% in this population in response to once daily iGlarLixi.
Journal ArticleDOI
Editorial Cycles and Continuity of Diabetes Care.
Matthew C. Riddle,George L. Bakris,Lawrence Blonde,Andrew J.M. Boulton,Jessica R. Castle,Linda A. DiMeglio,Linda Gonder-Frederick,Frank Hu,Steven E. Kahn,Sanjay Kaul,Robert G. Moses,Stephen W. Rich,Julio Rosenstock,Elizabeth Selvin,Adrian Vella,Judith Wylie-Rosett +15 more
Journal ArticleDOI
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
David Z.I. Cherney,Ele Ferrannini,Guillermo E. Umpierrez,Anne L. Peters,Julio Rosenstock,David R. Powell,Michael J. Davies,Phillip Banks,Rajiv Agarwal +8 more
TL;DR: In this paper , the efficacy and safety of sotagliflozin, a dual inhibitor of sodiumglucose co-transporters 1 and 2, in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3) were evaluated.
Journal ArticleDOI
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Priyadarshini Balasubramanian,Walter N. Kernan,Kevin N. Sheth,Anne Pernille Ofstad,Julio Rosenstock,Christoph Wanner,Bernard Zinman,Michaela Mattheus,Nikolaus Marx,Silvio E. Inzucchi +9 more
TL;DR: In this paper , the authors investigated the differences in risk factor control in patients with Type 2 diabetes (T2D) with previous stroke versus coronary artery disease (CAD) from three diabetes cardiovascular outcome trials: CARMELINA, EMPA-REG, and CAROLINA.